New study checks muscle loss in lung patients on common meds

This pilot study looks at how anti-fibrotic medications affect body composition in people with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). Researchers will use bioelectrical impedance analysis (BIA) and muscle ultrasound to track changes in muscle and fat mass. The goal is to see if these tools are practical and acceptable for monitoring patients starting nintedanib or pirfenidone. About 30 adults will be followed for 4 months.